HRP950525A2 - USE OF vWF CONTAINING CONCENTRATE AS COMBINATION THERAPY WIHT ANTITHROMBOTIC AND FIBRINOLYTICS - Google Patents

USE OF vWF CONTAINING CONCENTRATE AS COMBINATION THERAPY WIHT ANTITHROMBOTIC AND FIBRINOLYTICS Download PDF

Info

Publication number
HRP950525A2
HRP950525A2 HRP4437544.1A HRP950525A HRP950525A2 HR P950525 A2 HRP950525 A2 HR P950525A2 HR P950525 A HRP950525 A HR P950525A HR P950525 A2 HRP950525 A2 HR P950525A2
Authority
HR
Croatia
Prior art keywords
vwf
bleeding
hirudin
fibrinolytics
wiht
Prior art date
Application number
HRP4437544.1A
Other languages
English (en)
Croatian (hr)
Inventor
Martin Reers
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of HRP950525A2 publication Critical patent/HRP950525A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP4437544.1A 1994-10-20 1995-10-18 USE OF vWF CONTAINING CONCENTRATE AS COMBINATION THERAPY WIHT ANTITHROMBOTIC AND FIBRINOLYTICS HRP950525A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (1)

Publication Number Publication Date
HRP950525A2 true HRP950525A2 (en) 1997-04-30

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP4437544.1A HRP950525A2 (en) 1994-10-20 1995-10-18 USE OF vWF CONTAINING CONCENTRATE AS COMBINATION THERAPY WIHT ANTITHROMBOTIC AND FIBRINOLYTICS

Country Status (20)

Country Link
US (1) US5571784A (hu)
EP (1) EP0713881A3 (hu)
JP (1) JPH08208504A (hu)
KR (1) KR960013383A (hu)
CN (1) CN1128168A (hu)
AU (1) AU708670B2 (hu)
CA (1) CA2160975A1 (hu)
CZ (1) CZ287878B6 (hu)
DE (1) DE4437544A1 (hu)
FI (1) FI954964A (hu)
HR (1) HRP950525A2 (hu)
HU (1) HU219595B (hu)
IL (1) IL115652A (hu)
NO (1) NO954175L (hu)
NZ (1) NZ280274A (hu)
PL (1) PL183182B1 (hu)
SK (1) SK129695A3 (hu)
TW (1) TW398977B (hu)
UY (1) UY24063A1 (hu)
ZA (1) ZA958838B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子(vWF)切断酵素
DE102008032361A1 (de) 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー/エス 低減されたvwf結合を有する因子viii分子
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
GB8823480D0 (en) * 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) * 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
IL109383A0 (en) * 1993-04-23 1994-07-31 Bio Technology General Corp Method for enhancing thrombolysis

Also Published As

Publication number Publication date
AU708670B2 (en) 1999-08-12
EP0713881A3 (de) 1996-08-21
PL183182B1 (pl) 2002-06-28
IL115652A (en) 2000-08-31
NO954175D0 (no) 1995-10-19
FI954964A (fi) 1996-04-21
PL311031A1 (en) 1996-04-29
JPH08208504A (ja) 1996-08-13
IL115652A0 (en) 1996-01-19
UY24063A1 (es) 1995-10-24
ZA958838B (en) 1996-05-13
HU9503031D0 (en) 1995-12-28
NZ280274A (en) 1997-01-29
CZ287878B6 (cs) 2001-03-14
HUT73762A (en) 1996-09-30
FI954964A0 (fi) 1995-10-18
NO954175L (no) 1996-04-22
HU219595B (hu) 2001-05-28
TW398977B (en) 2000-07-21
DE4437544A1 (de) 1996-04-25
CA2160975A1 (en) 1996-04-21
CN1128168A (zh) 1996-08-07
SK129695A3 (en) 1996-10-02
AU3430495A (en) 1996-05-02
US5571784A (en) 1996-11-05
EP0713881A2 (de) 1996-05-29
CZ271995A3 (en) 1996-05-15
KR960013383A (ko) 1996-05-22

Similar Documents

Publication Publication Date Title
Horrow et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.
Gawaz et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.
Woodman et al. Bleeding complications associated with cardiopulmonary bypass
Franchini The use of desmopressin as a hemostatic agent: a concise review
Horrow et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations
Johnson et al. Management of dental patients with bleeding disorders: review and update
CA2730290C (en) Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
US20080254147A1 (en) Method of providing hemostasis in anti-coagulated blood
CA2684075A1 (en) Providing hemostasis in anticoagulated blood by using zeolites
Macik et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study
JP3859176B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した組成物およびそれらの使用
HRP950525A2 (en) USE OF vWF CONTAINING CONCENTRATE AS COMBINATION THERAPY WIHT ANTITHROMBOTIC AND FIBRINOLYTICS
KR101241061B1 (ko) 고비율의 고분자량 다량체를 가진 폰 빌레브란트 인자를 함유하는 혈장 단백질 농축물의 용도
TWI441645B (zh) 作為新穎之局部用止血劑的活化型因子X(FXa)刺激劑
Chen et al. Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
JP2001181204A (ja) 血液凝固異常に基づく疾患の治療・予防用医薬組成物
Hannanb et al. Concomitant T reatment with Factor IX Concentrates and Antifibrinolytics in Hemophilia B
Shanthi CLOTTING FACTOR REPLACEMENT THERAPY
Gilmore et al. and Kenneth E. Lupi Jr.
Gawaz et al. Impaired Function of Platelet Membrane Glycoprotein lIb-Illa in End-Stage Renal Disease1’2
Boccardo et al. Coagulation problems in dialysis patients
Levy New Concepts in the Treatment and Prevention of Bleeding

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused